Antibiotic Development: Where Wall Street Guidance Is Watching FDA Guidances
This article was originally published in RPM Report
Executive Summary
FDA’s effort to create a clearer path for antibiotic development has produced a series of new guidance documents. Those guidances are making some products in development look well-positioned for regulatory review, and rekindling the interest on Wall Street in specialty antibiotic firms.
You may also be interested in...
GAIN Begins (Part 1): FDA Completes Turnaround On Antibiotic R&D
In less than two years, FDA has moved from requiring unrealistic approval standards for antibiotics to exploring innovative ways to shorten the pathway for the most-needed drugs. And, surprise: Congress is on board too. After 15 years, there is finally real momentum on antibiotic drug policy. But is it all enough to get companies back in the game?
Fair is Fair; But Science is Science
Theravance’s proposed new indication for Vibativ is not the first drug to fail because of evolving regulatory standards. It may, however, have provoked the clearest and most formal articulation of FDA’s views on the limits of “fairness” regarding drug development commitments when it comes to approval decisions.
FDA Continues To Clarify Antibiotic Requirements With New Guidance On Complicated UTI
A non-inferiority trial with a pre-specified non-inferiority margin is the most likely design for investigational antibacterial drugs targeted at cUTI, according to FDA draft guidance. Primary efficacy endpoint needs to include resolution of symptoms, on top of microbiological success.